Sanara MedTech Inc.

Good day, ladies and gentlemen, and welcome to the Sonara MedTech Inc. Second Quarter 2021 Results and Business Update Conference Call. All lines have been placed on a listen-only mode, and the floor will be open for questions and comments from the web and phone following the presentation. At this time, it is my pleasure to turn the floor over to your host, Callan Nichols, Director of Investor Relations at Sonara. Sir, the floor is yours.

Thank you, Karen, and good morning, everyone. I'd like to welcome you to the Senara MedTechs earnings conference call for the quarter ending June 30th, 2021. We issued our earnings release yesterday afternoon, and I would like to also highlight that we have posted a link to today's deck on our investor relations page. This supplemental deck, as well as a copy of the earnings release, the 10-Q, and a transcript of this call will be available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, the chairman of our board, Mike McNeil, the chief financial officer, and Zach Fleming, president of Surgical, to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call and our press release and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding, among other things, the anticipated benefits of Rochelle asset acquisition, the development and approval of new products, and expansion of the company's business in telehealth and wound care. For more information about the risks and uncertainties involving forward-looking statements, please see our most recent Form 10-Q and annual report on Form 10-K. Now I'd like to turn the call over to Ron. Ron, the floor is yours.

Thank you, Callan, and good morning, everyone. I'll start with an overview of the second quarter, and then we'll dive more deeply into each topic in the subsequent slides. Sonera generated $6.3 million in sales and a net loss of $1.2 million in the second quarter of 2021. This was the fourth record revenue quarter in a row for the company and was driven by continued growth in surgical product sales. Surgical team has continued to focus on hospital approvals, product adoption, and adding high-quality experience regional and territorial sales managers to our team. Zach will discuss the specifics in his remarks. We continue to see strong growth and significant opportunity for our products in surgical pending no long-term effects of the COVID-19 virus or its variants. We're constantly focused on our product pipeline and bringing to market highly efficacious solutions that offer a good value proposition We continue to seek out partners who have proprietary products that fit within our six focus areas. In addition, following the acquisition of Rochelle Assets, we now have numerous development projects in-house. We intend to submit 510K applications for several of these products in our pipeline within the next 24 to 36 months. I'd like to discuss our telemedicine and virtual care businesses. We renamed United Wound and Skin Solutions to Wounderm, which we feel is a more appropriate name. Previously, Wounderm referred only to our proprietary wound and skin EMR and mobile app. The team at Wounderm is actively engaged in discussions regarding multiple pilots to prove the efficacy of Wounderm solutions and demonstrate the company's overall value proposition related to cost and outcomes of its comprehensive wound and skin strategy. Subsequent to the end of the quarter, we completed the acquisition of certain assets for our research and development partner, Rochelle Industries. We believe this acquisition will be an important contributor to our future development and growth plans, and it was structured as a win-win between the parties. With that overview, I'd now like to turn it over to Zach Fleming to discuss our surgical business and the latest on our partnership with Koch Biotech. Thanks, Ron.